The study is likely to enroll approximately 36 patients at multiple centers in the United States. Provided the encouraging efficacy and security we have observed with CAL-101 in our ongoing single-agent trial, it really is a logical next step to evaluate the protection and efficacy of the addition of CAL-101 to current regular of treatment regimens, stated Carol Gallagher, CEO of Calistoga Pharmaceuticals. CAL-101 can be an oral, small molecule delta selective PI3 kinase inhibitor, an initial in class compound, with higher than 200-fold selectivity in cell-based assays for the delta isoform in comparison with other class 1 PI3K isoforms.Blasetto, MD, chairman of the AstraZeneca Health care Foundation. ‘Boston INFIRMARY is developing innovative heart-healthy applications tailored to meet the average person needs of the city.’ ‘Partnering with Boston INFIRMARY will enable the YMCA to help expand its mission to aid healthful living and help people make changes in lifestyle for a better standard of living,’ added YMCA CEO Kevin Washington. This program was in the beginning launched because of the achievement of two prior pilot applications that showed that one lifestyle changes, such as revised exercise and diet, could be successfully implemented via an individualized program to lessen the incidence of diabetes and coronary disease significantly.